Literature DB >> 1933158

Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours.

J Vicente1, M P Laguna, D Duarte, F Algaba, G Chéchile.   

Abstract

G3pT1 bladder cancer has traditionally been regarded as a superficial tumour with a high risk of progression. We have studied 37 patients with initial G3pT1 bladder tumours treated between January 1981 and December 1985. They were divided into 2 groups according to the association with carcinoma in situ (Cis) at the time of diagnosis. Clinical behaviour was analysed at 5 years. The first group (without Cis) showed progression and recurrence rates similar to those of low grade, low stage bladder tumours. The second group (with Cis) had a similar rate of recurrence but their progression rate was 65%.

Entities:  

Mesh:

Year:  1991        PMID: 1933158     DOI: 10.1111/j.1464-410x.1991.tb15355.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  5 in total

1.  Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy.

Authors:  Erfan Amini; Nariman Ahmadi; Thomas G Clifford; Cory M Hugen; Soroush T Bazargani; Jie Cai; Gus Miranda; Andy E Sherrod; Siamak Daneshmand; Hooman Djaladat
Journal:  Int Urol Nephrol       Date:  2019-01-31       Impact factor: 2.370

2.  T1G3 bladder cancer--indications for early cystectomy.

Authors:  S Masood; S Sriprasad; J H Palmer; G R Mufti
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

3.  Growth pattern in superficial urothelial bladder carcinomas. Histological review and clinical relevance.

Authors:  José I López; Javier C Angulo
Journal:  Int Urol Nephrol       Date:  2009-03-12       Impact factor: 2.370

Review 4.  Immunotherapy for bladder cancer.

Authors:  A M Kamat; D L Lamm
Journal:  Curr Urol Rep       Date:  2001-02       Impact factor: 2.862

Review 5.  Superficial bladder cancer.

Authors:  Donald L Lamm
Journal:  Curr Treat Options Oncol       Date:  2002-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.